

7. N-{4-[2-Amino-5-(3,4-dimethoxyphenyl)pyridin-3-yl]phenyl}-5-(4-fluorophenyl)-4-oxo-1-(2,2,2-trifluoroethyl)-1,4-dihydropyridine-3-carboxamide or a salt thereof.
8. N-{4-[2-Amino-5-(3,4-dimethoxyphenyl)pyridin-3-yl]phenyl}-5-(4-fluorophenyl)-4-oxo-1-(2,2,2-trifluoroethyl)-1,4-dihydropyridine-3-carboxamide hydrochloride.
9. A crystal of N-{4-[2-amino-5-(3,4-dimethoxyphenyl)pyridin-3-yl]phenyl}-5-(4-fluorophenyl)-4-oxo-1-(2,2,2-trifluoroethyl)-1,4-dihydropyridine-3-carboxamide hydrochloride.
10. A crystal according to claim 9, which has an X-ray diffraction pattern shown in FIG. 1 in a powder X-ray diffraction diagram obtained by irradiation with copper $K\alpha$ radiation (wavelength $\lambda = 1.54 \text{ \AA}$).
11. A crystal according to claim 9, which has an X-ray diffraction pattern shown in FIG. 2 in a powder X-ray diffraction diagram obtained by irradiation with copper $K\alpha$ radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

12. A crystal according to claim 9, which has an X-ray diffraction pattern shown in FIG. 3 in a powder X-ray diffraction diagram obtained by irradiation with copper K α radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

13. A crystal according to claim 9, which has an X-ray diffraction pattern shown in FIG. 4 in a powder X-ray diffraction diagram obtained by irradiation with copper K α radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

14. A crystal according to claim 9, which has an X-ray diffraction pattern shown in FIG. 5 in a powder X-ray diffraction diagram obtained by irradiation with copper K α radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

15. A crystal according to claim 9, which has an X-ray diffraction pattern shown in FIG. 6 in a powder X-ray diffraction diagram obtained by irradiation with copper K α radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

16. A crystal according to claim 9, which has an X-ray diffraction pattern shown in FIG. 7 in a powder X-ray diffraction diagram obtained by irradiation with copper K α radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

17. A crystal according to claim 9, which has an X-ray diffraction pattern shown in FIG. 8 in a powder X-ray

diffraction diagram obtained by irradiation with copper $K\alpha$ radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

18. A crystal according to claim 9, which has an X-ray diffraction pattern shown in FIG. 9 in a powder X-ray diffraction diagram obtained by irradiation with copper $K\alpha$ radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

19. A crystal according to claim 9, which has an X-ray diffraction pattern shown in FIG. 10 in a powder X-ray diffraction diagram obtained by irradiation with copper $K\alpha$ radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

20. A crystal according to claim 9, which has an X-ray diffraction pattern shown in FIG. 11 in a powder X-ray diffraction diagram obtained by irradiation with copper $K\alpha$ radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

21. A crystal according to claim 9, which has an X-ray diffraction pattern shown in FIG. 12 in a powder X-ray diffraction diagram obtained by irradiation with copper $K\alpha$ radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

22. A crystal according to claim 9, which has an X-ray diffraction pattern shown in FIG. 13 in a powder X-ray diffraction diagram obtained by irradiation with copper $K\alpha$ radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

23. A crystal according to claim 9, which has an X-ray diffraction pattern shown in FIG. 14 in a powder X-ray diffraction diagram obtained by irradiation with copper K α radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

24. A crystal according to claim 9, which has an X-ray diffraction pattern shown in FIG. 15 in a powder X-ray diffraction diagram obtained by irradiation with copper K α radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

25. A crystal according to claim 9, which has an X-ray diffraction pattern shown in FIG. 16 in a powder X-ray diffraction diagram obtained by irradiation with copper K α radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

26. A crystal according to claim 9, which has characteristic peaks at diffraction angles 2θ of 7.44, 10.00, 13.48, 14.86, 16.10, 19.30, 20.30, 22.62, 23.02, 23.70, 24.54, 25.92 and 28.46 in a powder X-ray diffraction diagram obtained by irradiation with copper K α radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

27. A crystal according to claim 9, which has characteristic peaks at diffraction angles 2θ of 4.32, 9.10, 15.52, 18.32, 18.54, 19.22, 20.54, 20.70, 23.54, 24.14, 25.34 and 27.02 in a powder X-ray diffraction

diagram obtained by irradiation with copper K α radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

28. A crystal according to claim 9, which has characteristic peaks at diffraction angles 2θ of 13.86, 15.04, 19.76, 20.58, 22.26, 22.58, 23.82, 24.10, 24.36 and 24.88 in a powder X-ray diffraction diagram obtained by irradiation with copper K α radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

29. A crystal according to claim 9, which has characteristic peaks at diffraction angles 2θ of 5.34, 7.22, 8.20, 11.68, 14.54, 15.74, 17.54, 23.24, 23.72, 25.12 and 26.16 in a powder X-ray diffraction diagram obtained by irradiation with copper K α radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

30. A crystal according to claim 9, which has characteristic peaks at diffraction angles 2θ of 11.02, 11.86, 15.56, 18.20, 22.12, 24.70, 25.80, 26.04, 26.26 and 28.62 in a powder X-ray diffraction diagram obtained by irradiation with copper K α radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

31. A crystal according to claim 9, which has characteristic peaks at diffraction angles 2θ of 3.58, 4.56, 6.60, 6.72, 7.20, 9.62, 10.28, 13.06 and 24.52 in a

powder X-ray diffraction diagram obtained by irradiation with copper K α radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

32. A crystal according to claim 9, which has characteristic peaks at diffraction angles 2θ of 7.78, 8.14, 8.88, 12.54, 15.68, 16.36, 18.76, 19.34, 20.08, 22.36, 24.66, 25.74, 26.70 and 28.02 in a powder X-ray diffraction diagram obtained by irradiation with copper K α radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

33. A crystal according to claim 9, which has characteristic peaks at diffraction angles 2θ of 5.78, 8.90, 13.66, 14.42, 16.84, 17.56, 19.26, 20.74, 22.42, 24.66, 25.12, 25.60 and 26.96 in a powder X-ray diffraction diagram obtained by irradiation with copper K α radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

34. A crystal according to claim 9, which has characteristic peaks at diffraction angles 2θ of 11.12, 14.82, 18.86, 20.32, 20.66, 21.64, 22.36, 22.68, 23.00, 24.10, 25.26 and 27.00 in a powder X-ray diffraction diagram obtained by irradiation with copper K α radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

35. A crystal according to claim 9, which has characteristic peaks at diffraction angles 2θ of 7.80, 12.18, 12.78, 16.20, 16.82, 19.20, 19.66, 20.20, 21.20,

24.52, 25.68 and 26.78 in a powder X-ray diffraction diagram obtained by irradiation with copper K α radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

36. A crystal according to claim 9, which has characteristic peaks at diffraction angles 2θ of 2.80, 6.86, 7.88, 11.60, 13.68, 14.86, 17.40, 22.40, 23.78 and 25.74 in a powder X-ray diffraction diagram obtained by irradiation with copper K α radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

37. A crystal according to claim 9, which has characteristic peaks at diffraction angles 2θ of 5.32, 7.98, 10.68, 11.70, 14.84, 16.02, 19.78, 21.76, 23.08, 25.30 and 25.68 in a powder X-ray diffraction diagram obtained by irradiation with copper K α radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

38. A crystal according to claim 9, which has characteristic peaks at diffraction angles 2θ of 8.10, 10.60, 12.06, 14.16, 14.58, 15.60, 18.16, 20.72, 20.94, 22.86, 23.90, 24.32 and 27.14 in a powder X-ray diffraction diagram obtained by irradiation with copper K α radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

39. A crystal according to claim 9, which has characteristic peaks at diffraction angles 2θ of 3.60,

6.22, 9.56, 10.42, 14.04, 14.66, 15.30, 16.40, 19.52, 22.12 and 26.42 in a powder X-ray diffraction diagram obtained by irradiation with copper K α radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

40. A crystal according to claim 9, which has characteristic peaks at diffraction angles 2θ of 5.46, 7.98, 9.54, 11.00, 14.00, 15.36, 16.56, 22.00, 23.54, 24.00 and 26.56 in a powder X-ray diffraction diagram obtained by irradiation with copper K α radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

41. A crystal according to claim 9, which has characteristic peaks at diffraction angles 2θ of 5.64, 6.92, 8.06, 11.32, 14.40, 16.18, 17.04, 21.84, 22.50, 23.82 and 24.28 in a powder X-ray diffraction diagram obtained by irradiation with copper K α radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

42. An Axl inhibitor comprising a compound or salt thereof according to any one of claims 1 to 6, or a crystal thereof.

43. A medicine comprising a compound or salt thereof according to any one of claims 1 to 6, or a crystal thereof as an active ingredient.

44. A medicine for treating a disease caused by Axl kinase hyperfunction, a disease associated with Axl kinase hyperfunction and/or a disease accompanied by Axl kinase hyperfunction, comprising a compound or salt thereof according to any one of claims 1 to 6, or a crystal thereof as an active ingredient.

45. A medicine for treating hyperproliferative disease, comprising a compound or salt thereof according to any one of claims 1 to 6, or a crystal thereof as an active ingredient.

46. A medicine for treating cancer, comprising a compound or salt thereof according to any one of claims 1 to 6, or a crystal thereof as an active ingredient.

47. A medicine for preventing cancer metastasis, comprising a compound or salt thereof according to any one of claims 1 to 6, or a crystal thereof as an active ingredient.

48. A medicine for overcoming drug resistance, comprising a compound or salt thereof according to any one of claims 1 to 6, or a crystal thereof as an active ingredient.

49. A medicine according to claim 46 or 47, wherein the cancer is selected from breast cancer, colon cancer, prostate cancer, lung cancer, gastric cancer, ovarian cancer, endometrial cancer, renal cancer, hepatocellular carcinoma, thyroid cancer, uterine cancer, esophageal cancer, squamous cell carcinoma, leukemia, osteosarcoma, melanoma, glioblastoma, neuroblastoma and pancreatic cancer.

50. A pharmaceutical composition comprising a compound or salt thereof according to any one of claims 1 to 6, or a crystal thereof, and a pharmaceutically acceptable carrier.

51. A method for treating a disease caused by Axl kinase hyperfunction, a disease associated with Axl kinase hyperfunction and/or a disease accompanied by Axl kinase hyperfunction, comprising using a compound or salt thereof according to any one of claims 1 to 6, or a crystal thereof.

52. A method for treating hyperproliferative disease, comprising using a compound or salt thereof according to any one of claims 1 to 6, or a crystal thereof.

53. A method for treating cancer, comprising using a compound or salt thereof according to any one of claims 1 to 6, or a crystal thereof.

54. A method for preventing cancer metastasis, comprising using a compound or salt thereof according to any one of claims 1 to 6, or a crystal thereof.

55. A method for overcoming drug resistance, comprising using a compound or salt thereof according to any one of claims 1 to 6, or a crystal thereof.

56. A method according to claim 53 or 54, wherein the cancer is selected from breast cancer, colon cancer, prostate cancer, lung cancer, gastric cancer, ovarian cancer, endometrial cancer, renal cancer, hepatocellular carcinoma, thyroid cancer, uterine cancer, esophageal cancer, squamous cell carcinoma, leukemia, osteosarcoma, melanoma, glioblastoma and neuroblastoma.

57. Use of a compound or salt thereof according to any one of claims 1 to 6, or a crystal thereof for manufacturing a medicine.

58. Use of a compound or salt thereof according to any one of claims 1 to 6, or a crystal thereof for treating cancer.

59. Use of a compound or salt thereof according to any one of claims 1 to 6, or a crystal thereof for preventing cancer metastasis.

7. N-{4-[2-Amino-5-(3,4-dimethoxyphenyl)pyridin-3-yl]phenyl}-5-(4-fluorophenyl)-4-oxo-1-(2,2,2-trifluoroethyl)-1,4-dihydropyridine-3-carboxamide or a salt thereof.
8. N-{4-[2-Amino-5-(3,4-dimethoxyphenyl)pyridin-3-yl]phenyl}-5-(4-fluorophenyl)-4-oxo-1-(2,2,2-trifluoroethyl)-1,4-dihydropyridine-3-carboxamide hydrochloride.
9. A crystal of N-{4-[2-amino-5-(3,4-dimethoxyphenyl)pyridin-3-yl]phenyl}-5-(4-fluorophenyl)-4-oxo-1-(2,2,2-trifluoroethyl)-1,4-dihydropyridine-3-carboxamide hydrochloride.
10. A crystal according to claim 9, which has an X-ray diffraction pattern shown in any one of Figures 1 to 16 in a powder X-ray diffraction diagram obtained by irradiation with copper K α radiation (wavelength $\lambda = 1.54 \text{ \AA}$).
11. A crystal according to claim 9, which has characteristic peaks at diffraction angles 2θ of 7.44, 10.00, 13.48, 14.86, 16.10, 19.30, 20.30, 22.62, 23.02, 23.70, 24.54, 25.92 and 28.46 in a powder X-ray diffraction diagram obtained by irradiation with copper K α radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

12. A crystal according to claim 9, which has characteristic peaks at diffraction angles 2θ of 4.32, 9.10, 15.52, 18.32, 18.54, 19.22, 20.54, 20.70, 23.54, 24.14, 25.34 and 27.02 in a powder X-ray diffraction diagram obtained by irradiation with copper $K\alpha$ radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

13. A crystal according to claim 9, which has characteristic peaks at diffraction angles 2θ of 13.86, 15.04, 19.76, 20.58, 22.26, 22.58, 23.82, 24.10, 24.36 and 24.88 in a powder X-ray diffraction diagram obtained by irradiation with copper $K\alpha$ radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

14. A crystal according to claim 9, which has characteristic peaks at diffraction angles 2θ of 5.34, 7.22, 8.20, 11.68, 14.54, 15.74, 17.54, 23.24, 23.72, 25.12 and 26.16 in a powder X-ray diffraction diagram obtained by irradiation with copper $K\alpha$ radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

15. A crystal according to claim 9, which has characteristic peaks at diffraction angles 2θ of 11.02, 11.86, 15.56, 18.20, 22.12, 24.70, 25.80, 26.04, 26.26 and

28.62 in a powder X-ray diffraction diagram obtained by irradiation with copper K α radiation (wavelength $\lambda = 1.54$ Å).

16. A crystal according to claim 9, which has characteristic peaks at diffraction angles 2θ of 3.58, 4.56, 6.60, 6.72, 7.20, 9.62, 10.28, 13.06 and 24.52 in a powder X-ray diffraction diagram obtained by irradiation with copper K α radiation (wavelength $\lambda = 1.54$ Å).

17. A crystal according to claim 9, which has characteristic peaks at diffraction angles 2θ of 7.78, 8.14, 8.88, 12.54, 15.68, 16.36, 18.76, 19.34, 20.08, 22.36, 24.66, 25.74, 26.70 and 28.02 in a powder X-ray diffraction diagram obtained by irradiation with copper K α radiation (wavelength $\lambda = 1.54$ Å).

18. A crystal according to claim 9, which has characteristic peaks at diffraction angles 2θ of 5.78, 8.90, 13.66, 14.42, 16.84, 17.56, 19.26, 20.74, 22.42, 24.66, 25.12, 25.60 and 26.96 in a powder X-ray diffraction diagram obtained by irradiation with copper K α radiation (wavelength $\lambda = 1.54$ Å).

19. A crystal according to claim 9, which has characteristic peaks at diffraction angles 2θ of 11.12, 14.82, 18.86, 20.32, 20.66, 21.64, 22.36, 22.68, 23.00, 24.10, 25.26 and 27.00 in a powder X-ray diffraction diagram obtained by irradiation with copper $K\alpha$ radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

20. A crystal according to claim 9, which has characteristic peaks at diffraction angles 2θ of 7.80, 12.18, 12.78, 16.20, 16.82, 19.20, 19.66, 20.20, 21.20, 24.52, 25.68 and 26.78 in a powder X-ray diffraction diagram obtained by irradiation with copper $K\alpha$ radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

21. A crystal according to claim 9, which has characteristic peaks at diffraction angles 2θ of 2.80, 6.86, 7.88, 11.60, 13.68, 14.86, 17.40, 22.40, 23.78 and 25.74 in a powder X-ray diffraction diagram obtained by irradiation with copper $K\alpha$ radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

22. A crystal according to claim 9, which has characteristic peaks at diffraction angles 2θ of 5.32, 7.98, 10.68, 11.70, 14.84, 16.02, 19.78, 21.76, 23.08, 25.30 and 25.68 in a powder X-ray diffraction diagram

obtained by irradiation with copper K α radiation
(wavelength $\lambda = 1.54 \text{ \AA}$).

23. A crystal according to claim 9, which has
characteristic peaks at diffraction angles 2θ of 8.10,
10.60, 12.06, 14.16, 14.58, 15.60, 18.16, 20.72, 20.94,
22.86, 23.90, 24.32 and 27.14 in a powder X-ray
diffraction diagram obtained by irradiation with copper K α
radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

24. A crystal according to claim 9, which has
characteristic peaks at diffraction angles 2θ of 3.60,
6.22, 9.56, 10.42, 14.04, 14.66, 15.30, 16.40, 19.52,
22.12 and 26.42 in a powder X-ray diffraction diagram
obtained by irradiation with copper K α radiation
(wavelength $\lambda = 1.54 \text{ \AA}$).

25. A crystal according to claim 9, which has
characteristic peaks at diffraction angles 2θ of 5.46,
7.98, 9.54, 11.00, 14.00, 15.36, 16.56, 22.00, 23.54,
24.00 and 26.56 in a powder X-ray diffraction diagram
obtained by irradiation with copper K α radiation
(wavelength $\lambda = 1.54 \text{ \AA}$).

26. A crystal according to claim 9, which has characteristic peaks at diffraction angles 2θ of 5.64, 6.92, 8.06, 11.32, 14.40, 16.18, 17.04, 21.84, 22.50, 23.82 and 24.28 in a powder X-ray diffraction diagram obtained by irradiation with copper $K\alpha$ radiation (wavelength $\lambda = 1.54 \text{ \AA}$).

27. An Axl inhibitor comprising a compound or salt thereof according to any one of claims 1 to 6, or a crystal thereof.

28. A medicine comprising a compound or salt thereof according to any one of claims 1 to 6, or a crystal thereof as an active ingredient.

29. A medicine for treating a disease caused by Axl kinase hyperfunction, a disease associated with Axl kinase hyperfunction and/or a disease accompanied by Axl kinase hyperfunction, comprising a compound or salt thereof according to any one of claims 1 to 6, or a crystal thereof as an active ingredient.

30. A medicine for treating hyperproliferative disease, treating cancer, preventing cancer metastasis or overcoming drug resistance, comprising a compound or salt

thereof according to any one of claims 1 to 6, or a crystal thereof as an active ingredient.

31. A medicine according to claim 30, wherein the cancer is selected from breast cancer, colon cancer, prostate cancer, lung cancer, gastric cancer, ovarian cancer, endometrial cancer, renal cancer, hepatocellular carcinoma, thyroid cancer, uterine cancer, esophageal cancer, squamous cell carcinoma, leukemia, osteosarcoma, melanoma, glioblastoma, neuroblastoma and pancreatic cancer.

32. A pharmaceutical composition comprising a compound or salt thereof according to any one of claims 1 to 6, or a crystal thereof, and a pharmaceutically acceptable carrier.

33. Use of a compound or salt thereof according to any one of claims 1 to 6, or a crystal thereof for manufacturing a medicine.

34. Use of a compound or salt thereof according to any one of claims 1 to 6, or a crystal thereof for the manufacture of a medicine for treating cancer.

35. Use of a compound or salt thereof according to any one of claims 1 to 6, or a crystal thereof for the manufacture of a medicine for preventing cancer metastasis.